Immune Cell Regeneration and Gaining Strength to Attack Multiple Myeloma Cancer
Bibliographic record
Abstract
Multiple Myeloma is a rare cancer that primarily affects plasma cells that differentiate into white blood cells (which have important roles in the immune system such as fighting off infections and diseases). Once these plasma cells are transformed into cancerous cells that invade the space of the bone marrow, there is a prevention of the existence of future healthy immune cells that help the human body systems. Due to these viscous effects of the Multiple Myeloma, the blood cell count decreases and patients’ immunity lowers. The weakened immune systems of patients can attack the components of the treatments which leads to the wastage of money, time, and energy of the patients and the medical professionals. With the current research, patients can gain back strength and improve their immune systems. By the usage of the regeneration of stem cells, immunotherapy to increase the resistance of immune cells against the cancer, Chimeric Antigen Receptor T Cell therapy (or CAR-T Cell Therapy), and monoclonal antibody therapies, patients can gain back strength and improve their immune systems in a way that attacks Multiple Myeloma. Yet there is still growth for improvement, since the process of patients receiving treatments must be repeated multiple times due to the intensity and persistence of this cancer. By studying and researching the effects of Multiple Myeloma on immune cells, this paper’s goal is to find ways to improve current treatments and how to regenerate stronger and healthier immune cells which can resist and potentially defeat Multiple Myeloma Cancer.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.001 | 0.001 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.000 | 0.001 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.002 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".